LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Strona główna・Stock List・Puma Biotechnology Inc

Puma Biotechnology Inc

Closed

SectorHealthcare

6.82 0.15

Buy Sell

Overview

Share price change

24h

Current

Min

6.74

Max

6.83

Key metrics
By Trading Economics
Income	3M 8.8M
Sales	2M 54M
P/E Sector Avg	9.297 121.746
Profit margin	16.235
Employees	172
EBITDA	2.7M 13M

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	93M 347M
Previous open	6.67
Previous close	6.82

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

3.07 / 3.075 Support & Resistance

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 lut 2026, 22:17 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1st Half Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16 lut 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 lut 2026, 23:48 UTC

Market Talk

Nikkei May Decline; Prime Minister Takaichi's Policy Steps in Focus -- Market Talk

16 lut 2026, 23:23 UTC

Acquisitions, Mergers, Takeovers

BHP Shares Up 7.0% After Silver Streaming Deal, Profit Beat

16 lut 2026, 23:20 UTC

Acquisitions, Mergers, Takeovers

BHP Exploring Other Infrastructure Deals as It Chases $10 Billion Target - Interview

16 lut 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Brokers Value BHP's Total Stake in Antamina Around $4.5 Billion

16 lut 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Has Desalination, Other Power Assets on Which Deals Could Be Considered

16 lut 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Wants to Make Sure It Does Not Give Up Any Strategic, Operational Control of Assets

16 lut 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Will Allocate Cash From Asset Deals to Growth, Shareholder Returns

16 lut 2026, 22:47 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Won't Put Deadline on $10 Billion Cash Unlock Target

16 lut 2026, 22:47 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Bar Very High For Asset Deals

16 lut 2026, 22:47 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Sees 'Quite a Lot of Opportunities' in Potential Infrastructure Deals

16 lut 2026, 22:35 UTC

Market Talk

Australian Jobs Data Could Confirm Market Too Tight -- Market Talk

16 lut 2026, 22:02 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1H Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16 lut 2026, 21:48 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: Optimistic That Economic Backdrop Supportive For Key Commodities

16 lut 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals: Acquisition Immediately Increases Production and Cash Flow Profile

16 lut 2026, 21:48 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: China's Economy Resilient; India Continues to Outperform

16 lut 2026, 21:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: Streaming, WAIO Power Deals Unlock Over $6 Billion of Cash Combined

16 lut 2026, 21:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: Sees Potential to Unlock Up to $10 Billion From Portfolio, Asset Management

16 lut 2026, 21:47 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals to Have Combined 67.5% of All the Silver Produced From Antamina, Up From 33.75% Currently

16 lut 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals: Upfront Payment to Be Funded Through Combination of Existing Liquidity and New Financing

16 lut 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals Will Pay BHP Total Upfront Cash Consideration of $4.3B on Closing

16 lut 2026, 21:46 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP Interim Dividend Represents 60% Payout Ratio

16 lut 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals in Definitive Precious Metals Purchase Agreement BHP Subsidiary for Its 33.75% Portion of Silver Produced at Antamina Mine in Peru

16 lut 2026, 21:45 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: Copper Contributed 51% of 1H Underlying Ebitda

16 lut 2026, 21:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP Net Debt $14.69 Billion at Dec. 31, Up 25% On-Year

16 lut 2026, 21:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1H Net Operating Cash Flow $9.37 Billion, Up 13% On-Year

16 lut 2026, 21:42 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1H Underlying Ebitda $15.46 Billion, Up 25% On-Year

16 lut 2026, 21:42 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP Was Expected to Record Underlying Profit of $6.03 Billion According to Visible Alpha

16 lut 2026, 21:41 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1H Underlying Profit $6.20 Billion, Up 22% On-Year

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Rating Consensus

By TipRanks

0 ratings

Buy

Hold

Sell

Based on 0 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Recent bullish events outweigh bearish events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.